KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Asset Writedowns and Impairment (2020 - 2025)

Biogen has reported Asset Writedowns and Impairment over the past 10 years, most recently at $52.9 million for Q4 2025.

  • Quarterly results put Asset Writedowns and Impairment at $52.9 million for Q4 2025, up 323.2% from a year ago — trailing twelve months through Dec 2025 was $63.7 million (up 5.81% YoY), and the annual figure for FY2025 was $52.9 million, down 12.13%.
  • Asset Writedowns and Impairment for Q4 2025 was $52.9 million at Biogen, up from $3.5 million in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for BIIB hit a ceiling of $350.0 million in Q2 2021 and a floor of $3.5 million in Q2 2025.
  • Median Asset Writedowns and Impairment over the past 5 years was $27.5 million (2024), compared with a mean of $110.7 million.
  • Biggest five-year swings in Asset Writedowns and Impairment: skyrocketed 2210.92% in 2022 and later plummeted 93.67% in 2023.
  • Biogen's Asset Writedowns and Impairment stood at $120.0 million in 2021, then skyrocketed by 129.17% to $275.0 million in 2022, then crashed by 54.76% to $124.4 million in 2023, then plummeted by 89.95% to $12.5 million in 2024, then surged by 323.2% to $52.9 million in 2025.
  • The last three reported values for Asset Writedowns and Impairment were $52.9 million (Q4 2025), $3.5 million (Q2 2025), and $7.3 million (Q1 2025) per Business Quant data.